{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:05:12Z","timestamp":1779725112791,"version":"3.53.1"},"reference-count":18,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Although perioperative FLOT improves outcomes in locally advanced gastric cancer, postoperative recurrence remains frequent. This study evaluated the prognostic value of a PET-derived SUVmax\/albumin ratio integrating tumor metabolism and nutritional status in patients treated with neoadjuvant FLOT. Materials and Methods: This retrospective single-center study included patients with gastric adenocarcinoma treated with neoadjuvant FLOT followed by curative gastrectomy between January 2017 and May 2025, using data obtained from existing medical records after ethical approval. Pre-treatment SUVmax from 18F-FDG PET\/CT and serum albumin were recorded to calculate the SUVmax\/albumin ratio. Progression-free survival (PFS) was the primary endpoint. Prognostic factors were analyzed using Cox regression, and discriminatory performance was assessed using receiver operating characteristic (ROC) analysis. Results: A total of 104 patients were included. During a median follow-up of 28 months (IQR, 16\u201346 months), 46 patients (44.2%) developed recurrence. Patients with recurrence had significantly lower serum albumin levels and higher PET SUVmax values and PET SUVmax\/albumin ratios (all p &lt; 0.001). In multivariable analysis, the PET SUVmax\/albumin ratio remained significantly associated with PFS (HR 1.71; 95% CI 1.33\u20132.21; p &lt; 0.001). ROC analysis demonstrated moderate discriminatory performance (AUC 0.733; 95% CI 0.638\u20130.815), while additional time-dependent ROC analyses yielded AUC values of 0.732 (95% CI 0.611\u20130.836) at 1 year and 0.829 (95% CI 0.694\u20130.947) at 3 years. Exploratory comparative analyses demonstrated that both PET SUVmax and serum albumin retained statistical significance when evaluated simultaneously in the same multivariable model. Conclusions: The pre-treatment PET SUVmax\/albumin ratio was significantly associated with PFS in patients with gastric cancer treated with neoadjuvant FLOT and may represent an exploratory composite prognostic biomarker requiring further prospective validation.<\/jats:p>","DOI":"10.3390\/medicina62050964","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T15:05:08Z","timestamp":1779721508000},"page":"964","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A PET-Derived SUVmax-to-Albumin Ratio Predicts Recurrence After Neoadjuvant FLOT in Gastric Cancer"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5638-1816","authenticated-orcid":false,"given":"Emine B.","family":"Eniseler","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Celal Bayar University, 45140 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6491-5395","authenticated-orcid":false,"given":"Bartu","family":"\u00c7etin","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Manisa City Hospital, 45040 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9317-942X","authenticated-orcid":false,"given":"Ferhat","family":"Ekinci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Celal Bayar University, 45140 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1857-593X","authenticated-orcid":false,"given":"Mustafa","family":"Sahbazlar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Celal Bayar University, 45140 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4859-7574","authenticated-orcid":false,"given":"Atike P.","family":"Erdogan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Celal Bayar University, 45140 Manisa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2\/3 trial","volume":"393","author":"Homann","year":"2019","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association (2023). Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer, 26, 1\u201325.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"110843","DOI":"10.1016\/j.ejrad.2023.110843","article-title":"Prognostic value of [18F]FDG PET\/CT on treatment response and progression-free survival of gastroesophageal cancer patients undergoing perioperative FLOT chemotherapy","volume":"163","author":"Mirshahvalad","year":"2023","journal-title":"Eur. J. Radiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"20681","DOI":"10.1038\/s41598-022-24877-0","article-title":"Prognostic value of the metabolic score obtained via [18F]FDG PET\/CT and a new prognostic staging system for gastric cancer","volume":"12","author":"Kim","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yolcu, S.T., G\u00fcnalt\u0131l\u0131, M., Yolcu, E.A., G\u00fczel, S.S., \u015eeng\u00fcl, N., Atc\u0131, M.M., Karaboyun, K., Erdem, G.U., Alan, \u00d6., and Demirci, N.S. (2026). Inflammatory and Nutritional Indices as Prognostic Markers in Locally Advanced Gastric Cancer Treated with Neoadjuvant FLOT: A Retrospective Multicenter Study. J. Clin. Med., 15.","DOI":"10.3390\/jcm15072574"},{"key":"ref_8","first-page":"e23972","article-title":"Effect of C-Reactive Protein-to-Albumin Ratio on Prognosis in Gastric Cancer Patients","volume":"14","author":"Alkurt","year":"2022","journal-title":"Cureus"},{"key":"ref_9","first-page":"4581","article-title":"Inflammation-based prognostic score as a predictor of postoperative gastric cancer recurrence","volume":"32","author":"Mohri","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Li, X., Fu, Z., Zhang, J., Xu, J., Wang, L., and Li, K. (2024). A novel integrated nutrition-combined prognostic index for predicting overall survival after radical gastrectomy. Front. Nutr., 11.","DOI":"10.3389\/fnut.2024.1438319"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_12","unstructured":"Amin, M.B., Edge, S.B., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., and Sullivan, D.C. (2017). AJCC Cancer Staging Manual, Springer. [8th ed.]."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.2147\/OTT.S138039","article-title":"Derived neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio may be better biomarkers for predicting overall survival of patients with advanced gastric cancer","volume":"10","author":"Song","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhou, X., Yin, K., Hong, H., Yi, H., and Li, L. (2025). Combined Predictive Value of GLIM-Defined Malnutrition and Preoperative Adipose Tissue 18F-FDG Uptake for Recurrence-Free Survival After Radical Gastrectomy in Patients with Gastric Cancer. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32060363"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lu, F.-Y., Huang, X., Zhang, K., Yin, X., Lv, Y., Du, Y.-C., Zhou, Q., Min, J.-Y., Jiao, Y.-J., and Xi, L.-T. (2025). Development and validation of a diagnostic and screening method for gastric cancer by combining new gastric cancer screening score and serum biomarkers: A prospective study. BMC Cancer, 26.","DOI":"10.1186\/s12885-025-15379-z"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"16717","DOI":"10.1038\/s41598-017-16955-5","article-title":"The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis","volume":"7","author":"Dolan","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejso.2015.08.164","article-title":"Predicting recurrence after curative resection for gastric cancer: External validation of the Italian Research Group for Gastric Cancer (GIRCG) prognostic scoring system","volume":"42","author":"Barchi","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: A framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/964\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T15:34:16Z","timestamp":1779723256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/5\/964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["medicina62050964"],"URL":"https:\/\/doi.org\/10.3390\/medicina62050964","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}